CHRISTIE ANDERSONDVM, MS, DACVIM, Board Certified Veterinary Oncologist
Dr. Christie Anderson is board certified in veterinary oncology.
She completed undergraduate work at Otterbein College in Westerville, Ohio where she earned a BA in art and interior design in 1993. After working as an interior designer in Bigfork, Montana for five years, she felt the pull of a career in veterinary medicine. She took the leap, followed her heart, and earned a Doctorate of Veterinary Medicine from Colorado State University in 2005.
While there Dr. Anderson received Colorado State University’s Outstanding Clinical Oncology Student Award. Upon graduation, she was selected for a one-year general rotating internship in small animal medicine, surgery and emergency medicine at Alameda East Veterinary Hospital in Denver, Colorado. She then returned to Colorado State University for an oncology clinical trials dedicated internship.
Dr. Anderson completed a 3-year medical oncology residency program, earning an MS degree at Washington State University in 2011. During her residency, she was selected “Outstanding House Officer” by fourth-year veterinary students in both 2010 and 2011 and received the Veterinary Cancer Society Resident Award for Clinical Science in 2010.
Dr. Anderson practiced veterinary oncology for two years at Alameda East Veterinary Hospital, followed by four years at Northwest Veterinary Specialists in Oregon before joining the WestVet specialty team in summer 2017.
Dr. Anderson provides a compassionate approach to cancer in companion animals with the goal of extending their lives, while providing a good quality of life. For owners facing a pet with a cancer diagnosis, Dr. Anderson strives to explain the type of cancer, treatment options available and help families select the best treatment plan.
While interested in a broad spectrum of veterinary oncology, Dr. Anderson has a special interest in the treatment of mast cell disease, osteosarcoma and lymphoma, as well as molecular targeted therapies.
She has published research articles in Veterinary Comparative Oncology, Journal of Veterinary Internal Medicine, and Clinical Cancer Research. She is a member of the Veterinary Cancer Society, American College of Veterinary Internal Medicine, and the American Veterinary Medical Association.
Dr. Anderson has family in the Treasure Valley and likes to spend her free time hiking, horseback riding and enjoying the outdoors.
Anderson CL, MacKay C, Roberts G, Fidel J. Comparison of abdominal ultrasound and magnetic resonance imaging for detection of abdominal lymphadenopathy in dogs with metastatic apocrine gland adenocarcinoma of the anal sac. Vet Comp Oncol. February 22, 2013.
Tripp CD, Fidel J, Anderson CL, Patrick M, Pratt C, Sellon R, Bryan JN. Tolerability of metronomic administration of lomustine in dogs with cancer. J Vet Intern Med 2011; 25:278′”284.
Shiu KB, Flory A, Anderson CL, Wypij J, Saba C, Wilson H, Kurzman I, Chun R. Predictors of outcome in dogs with subcutaneous or intramuscular hemangiosarcoma. Journal of the American Veterinary Medicine Association. JAVMA, Vol 238, No. 4, February 15, 2011.
Vail DM, Thamm DH, Reiser H, Ray AS, Wolfgang GH, Watkins WJ, Babusis D, Henne IN, Hawkins MJ, Kurzman ID, Jeraj R, Vanderhoek M, Plaza S, Anderson C, Wessel MA, Robat C, Lawrence J, Tumas DB. Assessment of GS-9219 in a pet dog model of non-Hodgkin’s lymphoma. Clin Cancer Res. 2009 May 15:15(10):3503-10.
SELECTED PRESENTATIONS/PEER-REVIEWED ABSTRACTS:
Comparision of Abdominal Ultrasound and Magnetic Resonance Imaging for Detection of Abdominal Lymphadenopathy in Dogs with Metastatic Anal Sac Gland Adenocarcinoma. Veterinary Cancer Society Annual Meeting, San Diego, CA, Oct 29-Nov 1, 2010. Received the VCS Resident Award for Clinical Science.
Bryan JN, Anderson CL, Jabbes M, Fidel J. Pretreatment with valproic acid increases radiation effect on lymphoma cells in vitro. Veterinary Cancer Society Annual Meeting, Austin, TX, Oct 16-19, 2009.
Vail DM, Thamm DH, Tumas DB, Reiser H, Ray AS, Watkins WJ, Kurzman ID, Jeraj R, Plaza S, Anderson C, Wessel MA. Efficacy and safety profile of GS-9219, a novel guanine nucleotide analog prodrug, for the treatment of lymphoid malignancies using pet dogs with spontaneous non-Hodgkin’s lymphoma as a model. Amer Asoc Cancer Res Annual Meeting, Los Angeles, CA, April 2007, Abstr #5730.
Thamm DH, Clark MA, Kurzman ID, Kraft SL, Gustafson DL, Plaza SM, Anderson C, Vail DM. Preclinical evaluation of PEGylated tumor necrosis factor alpha in dogs with spontaneous tumors: Results of phase-I investigation. AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics, San Francisco, CA, October 22-26, 2007.
Dernell WS, Thamm DH, Larue SM, Kraft SL, Ehrhart EJ, Plaza S, Anderson C, Ullrich RL. Evaluation of the effects of single, high-dose radiation with or without an immunomodulator for canine osteosarcoma. Proc Vet Cancer Soc, Ft. Lauderdale, FL, Nov 1-4, 2007.
Paoloni M, Tandle A, Mazcko C, Hanna E, LeBlanc A, Vail DM, Thamm DH, Henry C, Sorenmo K, Libutti S, Kurzman ID, Plaza S, Anderson C, Khanna C. Evaluation of activity and cumulative toxicity of systematically delivered tumor vasculature targeted AAVP TNF-A phage to dogs with spontaneous tumors. Proc Vet Cancer Soc, Ft. Lauderdale, FL, Nov 1-4, 2007.
Thamm DH, Tumas DB, Reiser H, Ray AS, Watkins WJ, Kurzman ID, Jeraj R, Plaza S, Anderson C, Wessel MA, Vail DM. Efficacy and safety profile of GS-9219, a novel guanine nucleotide analog prodrug, for the treatment of dogs with spontaneous non-Hodgkin’s lymphoma. Proc Vet Cancer Soc, Ft. Lauderdale, FL, Nov 1-4, 2007.
Thamm DH, Tumas DB, Reiser H, Wolgfang GHI, Kurzman ID, Plaza S, Anderson C, Robat C, Vail DM. GS-9219, a novel guanine nucleotide analog prodrug, has antitumor activity against naïve and melphalan-refractory spontaneous myeloma in pet dogs. Proc Am Soc Hematol, Orlando, FL, Dec 8-11, 2007.
Vail DM, Thamm DH, Tumas DB, Reiser H, Ray AS, Watkins WJ, Kurzman ID, Jeraj R, Plaza S, Anderson C, Wessel MA, Robat C, Lawrence J. A novel guanine nucleotide analog prodrug (GS-9219) demonstrates significant therapeutic activity against spontaneous non-Hodgkin’s lymphoma as modeled in pet dogs. Proc Am Soc Hematol, Orlando, FL, Dec 8-11, 2007.